FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137816642> ?p ?o ?g. }

• W2137816642 endingPage "549" @default.
• W2137816642 startingPage "541" @default.
• W2137816642 abstract "Diffuse large-B-cell lymphoma is curable, but when treatment fails, outcome is poor. Although imaging can help to identify patients at risk of treatment failure, they are often imprecise, and radiation exposure is a potential health risk. We aimed to assess whether circulating tumour DNA encoding the clonal immunoglobulin gene sequence could be detected in the serum of patients with diffuse large-B-cell lymphoma and used to predict clinical disease recurrence after frontline treatment.We used next-generation DNA sequencing to retrospectively analyse cell-free circulating tumour DNA in patients assigned to one of three treatment protocols between May 8, 1993, and June 6, 2013. Eligible patients had diffuse large-B-cell lymphoma, no evidence of indolent lymphoma, and were previously untreated. We obtained serial serum samples and concurrent CT scans at specified times during most treatment cycles and up to 5 years of follow-up. VDJ gene segments of the rearranged immunoglobulin receptor genes were amplified and sequenced from pretreatment specimens and serum circulating tumour DNA encoding the VDJ rearrangements was quantitated.Tumour clonotypes were identified in pretreatment specimens from 126 patients who were followed up for a median of 11 years (IQR 6·8-14·2). Interim monitoring of circulating tumour DNA at the end of two treatment cycles in 108 patients showed a 5-year time to progression of 41·7% (95% CI 22·2-60·1) in patients with detectable circulating tumour DNA and 80·2% (69·6-87·3) in those without detectable circulating tumour DNA (p<0·0001). Detectable interim circulating tumour DNA had a positive predictive value of 62·5% (95% CI 40·6-81·2) and a negative predictive value of 79·8% (69·6-87·8). Surveillance monitoring of circulating tumour DNA was done in 107 patients who achieved complete remission. A Cox proportional hazards model showed that the hazard ratio for clinical disease progression was 228 (95% CI 51-1022) for patients who developed detectable circulating tumour DNA during surveillance compared with patients with undetectable circulating tumour DNA (p<0·0001). Surveillance circulating tumour DNA had a positive predictive value of 88·2% (95% CI 63·6-98·5) and a negative predictive value of 97·8% (92·2-99·7) and identified risk of recurrence at a median of 3·5 months (range 0-200) before evidence of clinical disease.Surveillance circulating tumour DNA identifies patients at risk of recurrence before clinical evidence of disease in most patients and results in a reduced disease burden at relapse. Interim circulating tumour DNA is a promising biomarker to identify patients at high risk of treatment failure.National Cancer Institute and Adaptive Biotechnologies." @default.
• W2137816642 created "2016-06-24" @default.
• W2137816642 creator A5002368482 @default.
• W2137816642 creator A5002571777 @default.
• W2137816642 creator A5004367769 @default.
• W2137816642 creator A5006451293 @default.
• W2137816642 creator A5011726172 @default.
• W2137816642 creator A5021627028 @default.
• W2137816642 creator A5025942951 @default.
• W2137816642 creator A5039333571 @default.
• W2137816642 creator A5044239219 @default.
• W2137816642 creator A5044366730 @default.
• W2137816642 creator A5049385918 @default.
• W2137816642 creator A5054118827 @default.
• W2137816642 creator A5060885349 @default.
• W2137816642 creator A5075115200 @default.
• W2137816642 creator A5077947210 @default.
• W2137816642 creator A5089779163 @default.
• W2137816642 date "2015-05-01" @default.
• W2137816642 modified "2023-10-12" @default.
• W2137816642 title "Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study" @default.
• W2137816642 cites W105174668 @default.
• W2137816642 cites W1644997609 @default.
• W2137816642 cites W1892398095 @default.
• W2137816642 cites W1912693401 @default.
• W2137816642 cites W1971211622 @default.
• W2137816642 cites W1972151064 @default.
• W2137816642 cites W1978135177 @default.
• W2137816642 cites W1996805577 @default.
• W2137816642 cites W2001196047 @default.
• W2137816642 cites W2034698433 @default.
• W2137816642 cites W2039943360 @default.
• W2137816642 cites W2070232733 @default.
• W2137816642 cites W2097134772 @default.
• W2137816642 cites W2102472975 @default.
• W2137816642 cites W2109130949 @default.
• W2137816642 cites W2115637639 @default.
• W2137816642 cites W2126232974 @default.
• W2137816642 cites W2130929003 @default.
• W2137816642 cites W2133869962 @default.
• W2137816642 cites W2138874270 @default.
• W2137816642 cites W2150587745 @default.
• W2137816642 cites W2157982120 @default.
• W2137816642 cites W2168109746 @default.
• W2137816642 cites W2168205543 @default.
• W2137816642 cites W2171237493 @default.
• W2137816642 cites W2171697262 @default.
• W2137816642 cites W2322887557 @default.
• W2137816642 cites W2335942423 @default.
• W2137816642 cites W2598700764 @default.
• W2137816642 cites W4235642752 @default.
• W2137816642 cites W4293241248 @default.
• W2137816642 doi "https://doi.org/10.1016/s1470-2045(15)70106-3" @default.
• W2137816642 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4460610" @default.
• W2137816642 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25842160" @default.
• W2137816642 hasPublicationYear "2015" @default.
• W2137816642 type Work @default.
• W2137816642 sameAs 2137816642 @default.
• W2137816642 citedByCount "320" @default.
• W2137816642 countsByYear W21378166422015 @default.
• W2137816642 countsByYear W21378166422016 @default.
• W2137816642 countsByYear W21378166422017 @default.
• W2137816642 countsByYear W21378166422018 @default.
• W2137816642 countsByYear W21378166422019 @default.
• W2137816642 countsByYear W21378166422020 @default.
• W2137816642 countsByYear W21378166422021 @default.
• W2137816642 countsByYear W21378166422022 @default.
• W2137816642 countsByYear W21378166422023 @default.
• W2137816642 crossrefType "journal-article" @default.
• W2137816642 hasAuthorship W2137816642A5002368482 @default.
• W2137816642 hasAuthorship W2137816642A5002571777 @default.
• W2137816642 hasAuthorship W2137816642A5004367769 @default.
• W2137816642 hasAuthorship W2137816642A5006451293 @default.
• W2137816642 hasAuthorship W2137816642A5011726172 @default.
• W2137816642 hasAuthorship W2137816642A5021627028 @default.
• W2137816642 hasAuthorship W2137816642A5025942951 @default.
• W2137816642 hasAuthorship W2137816642A5039333571 @default.
• W2137816642 hasAuthorship W2137816642A5044239219 @default.
• W2137816642 hasAuthorship W2137816642A5044366730 @default.
• W2137816642 hasAuthorship W2137816642A5049385918 @default.
• W2137816642 hasAuthorship W2137816642A5054118827 @default.
• W2137816642 hasAuthorship W2137816642A5060885349 @default.
• W2137816642 hasAuthorship W2137816642A5075115200 @default.
• W2137816642 hasAuthorship W2137816642A5077947210 @default.
• W2137816642 hasAuthorship W2137816642A5089779163 @default.
• W2137816642 hasBestOaLocation W21378166422 @default.
• W2137816642 hasConcept C126322002 @default.
• W2137816642 hasConcept C142724271 @default.
• W2137816642 hasConcept C143998085 @default.
• W2137816642 hasConcept C159654299 @default.
• W2137816642 hasConcept C203014093 @default.
• W2137816642 hasConcept C2776694085 @default.
• W2137816642 hasConcept C2778559949 @default.
• W2137816642 hasConcept C2779338263 @default.
• W2137816642 hasConcept C2781197716 @default.
• W2137816642 hasConcept C3020196193 @default.
• W2137816642 hasConcept C55493867 @default.
• W2137816642 hasConcept C71924100 @default.

• next